Myelodysplastic syndrome with excess blasts
MONDO:0019454A myelodysplastic syndrome characterized by the presence of 5-19% myeloblasts in the bone marrow or 2-19% blasts in the peripheral blood. It includes two categories: myelodysplastic syndrome with excess blasts-1 and myelodysplastic syndrome with excess blasts-2.
Also known as: MDS-EB, RAEB, myelodysplastic syndrome with Excess blasts, refractory Anaemia with Excess blasts, refractory Anaemia with an Excess of blasts, refractory Anemia with Excess blasts, refractory Anemia with an Excess of blasts
1929 clinical trials for this condition and its sub-types, 72 tagged with Myelodysplastic syndrome with excess blasts itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myelodysplastic syndrome with excess blasts
-
Can a pill keep blood cancer at bay after a stem cell transplant?
Disease control CompletedThis phase III trial is testing whether taking oral azacitidine as a maintenance therapy after an allogeneic stem cell transplant can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Participants are randomly assigned to receive…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New stem cell transplant approach shows promise for blood cancer patients without full matches
Disease control CompletedThis Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…
Phase 3 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Bone marrow transplant breakthrough: more donors now possible for blood cancer patients?
Disease control CompletedThis study tested a gentler bone marrow transplant for people with blood cancers who don't have a perfectly matched family donor. Instead, it used donors who are less closely matched, like unrelated volunteers or distant relatives. The goal was to see if this approach could be sa…
Phase 1/2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Heart iron levels measured in Transfusion-Dependent patients
Knowledge-focused CompletedThis study measured how often iron builds up in the heart muscle of people who receive many blood transfusions. Researchers used MRI scans to check heart iron levels in 110 patients with thalassemia, sickle cell disease, or myelodysplasia. The goal was to understand how common th…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC